A human liver model to predict drug-induced liver injury
DDT-IST-000016-LOI-2 A Human Liver-Chip for Prediction of Drug-Induced Liver Injury proposed for context of use claim for the prediction of DILI within preclinical drug development program
This study is creating a tiny model of the human liver to see how different medications might harm the liver, which could help make sure that safer drugs are available for people like you before they are tested in real patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emulate, INC. NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11088687 on NIH RePORTER |
What this research studies
This research focuses on developing a human liver-chip model that can accurately predict drug-induced liver injury (DILI) during the drug development process. By using a quad-culture system that mimics the liver's cellular environment, the study aims to evaluate how different drugs affect liver cells, helping to identify potential risks before clinical trials. The liver-chip incorporates various cell types to recreate the complex interactions that occur in a real liver, providing a more reliable assessment of drug safety. This innovative approach could lead to safer drugs and better patient outcomes by preventing harmful drugs from reaching the market.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are involved in clinical trials for new drug candidates, particularly those with a history of liver-related health issues.
Not a fit: Patients who are not participating in clinical trials or who do not have any liver health concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance drug safety by reducing the incidence of drug-induced liver injuries in patients.
How similar studies have performed: Previous studies using organ-chip technology have shown promising results in predicting drug toxicity, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Emulate, INC. — Boston, United States (Active)
Researchers
- Principal investigator: Ewart, Lorna — Emulate, INC.
- Study coordinator: Ewart, Lorna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.